{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:47:34Z","timestamp":1773784054291,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharma KK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40744-025-00822-1","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:13:54Z","timestamp":1769768034000},"page":"361-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Fumio","family":"Akita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Seko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"9","key":"822_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","volume":"71","author":"A Martini","year":"2012","unstructured":"Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71(9):1437\u20139.","journal-title":"Ann Rheum Dis"},{"key":"822_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-015-0047-3","volume":"13","author":"N Nirmala","year":"2015","unstructured":"Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.","journal-title":"Pediatr Rheumatol Online J"},{"key":"822_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00467","volume":"7","author":"G Giancane","year":"2016","unstructured":"Giancane G, Minoia F, Davi S, et al. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467.","journal-title":"Front Pharmacol"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S114532","volume":"12","author":"N Toplak","year":"2018","unstructured":"Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Dev Ther. 2018;12:1633\u201343.","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"822_CR5","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Davi S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"822_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"822_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"822_CR8","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"6","key":"822_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/mr\/roac128","volume":"33","author":"N Iwata","year":"2023","unstructured":"Iwata N, Nishimura K, Hara R, et al. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: results from an open-label phase III study. Mod Rheumatol. 2023;33(6):1162\u201370.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"822_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/14397595.2020.1783163","volume":"31","author":"K Nishimura","year":"2021","unstructured":"Nishimura K, Hara R, Umebayashi H, et al. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients. Mod Rheumatol. 2021;31(1):226\u201334.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"822_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0147-3","volume":"15","author":"B Hugle","year":"2017","unstructured":"Hugle B, Speth F, Haas JP. Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2017;15(1):16.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"822_CR12","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3899\/jrheum.140472","volume":"42","author":"D Barthel","year":"2015","unstructured":"Barthel D, Ganser G, Kuester RM, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42(11):2160\u20135.","journal-title":"J Rheumatol"},{"issue":"4","key":"822_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3899\/jrheum.200230","volume":"48","author":"J Maller","year":"2021","unstructured":"Maller J, Fox E, Park KT, et al. Inflammatory bowel disease in children with systemic juvenile idiopathic arthritis. J Rheumatol. 2021;48(4):567\u201374.","journal-title":"J Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00822-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00822-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00822-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:05:59Z","timestamp":1773770759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00822-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00822-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fumio Akita, Noriko Seko and Tomohiro Yoneda are employees of Novartis Pharma K.K., Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted by Novartis Pharma K.K. according to the regulations of Good Post-marketing Study Practice as ordained by the Ministry of Health, Labour and Welfare, Japan, which determines that Institutional Review Board approval and informed consent are not necessarily required for conducting PMS in Japan. The study protocol was approved by a scientific\/ethical review committee of Novartis. Novartis Pharma K.K. provided the investigator with an information sheet describing the objective and content of this surveillance, protection of personal information, and publication of surveillance data, and the investigator explained the surveillance to patients using the information sheet before the start of treatment. All data used in this study were fully de-identified prior to analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}